Skip to main content

$0.049 0.007 (16.67%)

High

$0.05

Low

$0.04

Trades

74

Turnover

$48,318

Volume

1,094,468
30 June 2023 at 4:10pm
Register to track PXS and receive email alerts.
Subject
PXS Ann: Notification of cessation of securities - PXS

PXS Ann: Clarification Announcement

PXS Ann: Investor Presentation

PXS Ann: Quarterly Activities Report

PXS Ann: Appendix 4C Quarterly Cash Flow Report

PXS Ann: Pharmaxis Quarterly Investor Briefing

PXS Ann: R&D Showcase Presentations Webinar 2

PXS Ann: R&D Showcase Presentations Webinar 1

PXS Ann: Investor Presentation

PXS Ann: PXS Investor R&D Showcase Webinars

PXS Ann: PXS Launches New International Trial Sites in Cancer Trial

PXS Ann: Change in substantial holding

PXS Ann: Half Yearly Report and Accounts

PXS Ann: Updated Investor Presentation

PXS Ann: Presentation - quarterly investor update

PXS Ann: Quarterly Activities Report

PXS Ann: Quarterly Appendix 4C Cash Flow Report

PXS Ann: First Patients Dosed in PXS Scar Reduction Trial

PXS Ann: PXS Quarterly Shareholder Update and Investor Briefing

PXS Ann: Response to ASX Aware Query

PXS Ann: PXS Collaborators Receive Government Grants of $1.4m

PXS Ann: Change of Director's Interest Notice

PXS Ann: Change of Director's Interest Notice

PXS Ann: Change of Director's Interest Notice

PXS Ann: Application for quotation of securities - PXS

PXS Ann: Change of Director's Interest Notice

PXS Ann: Change of Director's Interest Notice

PXS Ann: Application for quotation of securities - PXS

PXS Ann: Share Purchase Plan

PXS Ann: Investor presentation

PXS Ann: Investor Briefing

PXS Ann: Application for quotation of securities - PXS

PXS Ann: Security Purchase Plan

PXS Ann: Section 708A(5)(e) Notice

PXS Ann: Application for quotation of securities - PXS

PXS Ann: Application for quotation of securities - PXS

PXS Ann: Proposed issue of securities - PXS

PXS Ann: Investor Presentation

PXS Ann: Proposed issue of securities - PXS

PXS Ann: Placement

PXS Article: Pharmaxis raising $9.2 million via Morgans

PXS Ann: Trading Halt

PXS Ann: FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer Study

PXS Ann: Notification regarding unquoted securities - PXS

PXS Ann: Investor Presentation

PXS Ann: Change of Director's Interest Notice

PXS Ann: Notification regarding unquoted securities - PXS

PXS Ann: Constitution as amended 3 November

PXS Ann: Results of Meeting

PXS Ann: CEO Presentation to 2021 AGM

Register to track PXS and receive email alerts.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
NEU
PBP
RCE
SPL